Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Epileptic and developmental disorders of the speech cortex: ligand/receptor interaction of wild-type and mutant SRPX2 with the plasminogen activator receptor uPAR.

Royer-Zemmour B, Ponsole-Lenfant M, Gara H, Roll P, Lévêque C, Massacrier A, Ferracci G, Cillario J, Robaglia-Schlupp A, Vincentelli R, Cau P, Szepetowski P.

Hum Mol Genet. 2008 Dec 1;17(23):3617-30. doi: 10.1093/hmg/ddn256. Epub 2008 Aug 21.

PMID:
18718938
2.

SRPX2 mutations in disorders of language cortex and cognition.

Roll P, Rudolf G, Pereira S, Royer B, Scheffer IE, Massacrier A, Valenti MP, Roeckel-Trevisiol N, Jamali S, Beclin C, Seegmuller C, Metz-Lutz MN, Lemainque A, Delepine M, Caloustian C, de Saint Martin A, Bruneau N, Depétris D, Mattéi MG, Flori E, Robaglia-Schlupp A, Lévy N, Neubauer BA, Ravid R, Marescaux C, Berkovic SF, Hirsch E, Lathrop M, Cau P, Szepetowski P.

Hum Mol Genet. 2006 Apr 1;15(7):1195-207. Epub 2006 Feb 23.

PMID:
16497722
4.

Molecular networks implicated in speech-related disorders: FOXP2 regulates the SRPX2/uPAR complex.

Roll P, Vernes SC, Bruneau N, Cillario J, Ponsole-Lenfant M, Massacrier A, Rudolf G, Khalife M, Hirsch E, Fisher SE, Szepetowski P.

Hum Mol Genet. 2010 Dec 15;19(24):4848-60. doi: 10.1093/hmg/ddq415. Epub 2010 Sep 21.

5.
6.

Molecular evolution of the human SRPX2 gene that causes brain disorders of the Rolandic and Sylvian speech areas.

Royer B, Soares DC, Barlow PN, Bontrop RE, Roll P, Robaglia-Schlupp A, Blancher A, Levasseur A, Cau P, Pontarotti P, Szepetowski P.

BMC Genet. 2007 Oct 18;8:72.

7.
8.

The urokinase receptor in the central nervous system.

Archinti M, Britto M, Eden G, Furlan F, Murphy R, Degryse B.

CNS Neurol Disord Drug Targets. 2011 Mar;10(2):271-94. Review.

PMID:
20874700
9.

Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.

Rasch MG, Pass J, Illemann M, Høyer-Hansen G, Lund IK.

J Immunol Methods. 2008 Nov 30;339(1):55-65. doi: 10.1016/j.jim.2008.08.002. Epub 2008 Aug 30.

PMID:
18761343
10.

The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.

Hildenbrand R, Schaaf A.

Int J Oncol. 2009 Jan;34(1):15-23.

PMID:
19082473
11.

Murine monoclonal antibodies against murine uPA receptor produced in gene-deficient mice: inhibitory effects on receptor-mediated uPA activity in vitro and in vivo.

Pass J, Jögi A, Lund IK, Rønø B, Rasch MG, Gårdsvoll H, Lund LR, Ploug M, Rømer J, Danø K, Høyer-Hansen G.

Thromb Haemost. 2007 Jun;97(6):1013-22.

PMID:
17549305
12.

Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.

Skeldal S, Larsen JV, Pedersen KE, Petersen HH, Egelund R, Christensen A, Jensen JK, Gliemann J, Andreasen PA.

FEBS J. 2006 Nov;273(22):5143-59. Epub 2006 Oct 17.

13.

Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion.

De Bock CE, Lin Z, Mekkawy AH, Byrne JA, Wang Y.

Int J Oncol. 2010 May;36(5):1155-63.

PMID:
20372789
14.

Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke.

Nagai N, Okada K, Kawao N, Ishida C, Ueshima S, Collen D, Matsuo O.

Neurosci Lett. 2008 Feb 13;432(1):46-9. doi: 10.1016/j.neulet.2007.12.004. Epub 2007 Dec 8.

PMID:
18164548
15.

The urokinase receptor interactome.

Eden G, Archinti M, Furlan F, Murphy R, Degryse B.

Curr Pharm Des. 2011;17(19):1874-89. Review.

PMID:
21711237
16.

Urokinase receptor variants in tissue and body fluids.

Høyer-Hansen G, Lund IK.

Adv Clin Chem. 2007;44:65-102. Review.

PMID:
17682340
17.

The uPA receptor and the somatomedin B region of vitronectin direct the localization of uPA to focal adhesions in microvessel endothelial cells.

Salasznyk RM, Zappala M, Zheng M, Yu L, Wilkins-Port C, McKeown-Longo PJ.

Matrix Biol. 2007 Jun;26(5):359-70. Epub 2007 Feb 6.

PMID:
17344041
18.

One-step affinity purification of recombinant urokinase-type plasminogen activator receptor using a synthetic peptide developed by combinatorial chemistry.

Jacobsen B, Gårdsvoll H, Juhl Funch G, Ostergaard S, Barkholt V, Ploug M.

Protein Expr Purif. 2007 Apr;52(2):286-96. Epub 2006 Aug 30.

PMID:
17027282
20.

IGF-II/mannose 6-phosphate receptor activation induces metalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.

Chang MH, Kuo WW, Chen RJ, Lu MC, Tsai FJ, Kuo WH, Chen LY, Wu WJ, Huang CY, Chu CH.

J Mol Endocrinol. 2008 Aug;41(2):65-74. doi: 10.1677/JME-08-0051. Epub 2008 May 21.

PMID:
18495691

Supplemental Content

Support Center